Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Zealand Pharma A/S (ZLDPF)

Zealand Pharma A/S (ZLDPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zealand Pharma A/S Sydmarken 11 Soborg Copenhagen G7 2860 DNK

www.zealandpharma.com P: 45-8877-3600

Description:

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.

Key Statistics

Overview:

Market Capitalization, $K 4,789,782
Enterprise Value, $K 4,695,212
Shares Outstanding, K 51,513
Annual Sales, $ 49,750 K
Annual Net Income, $ -102,130 K
Last Quarter Sales, $ 2,200 K
Last Quarter Net Income, $ -33,300 K
EBIT, $ -21,930 K
EBITDA, $ -101,840 K
60-Month Beta 0.67
% of Institutional Shareholders 0.00%
Float, K 51,513
% Float 100.00%
Short Volume Ratio 0.86

Growth:

1-Year Return 143.09%
3-Year Return 515.77%
5-Year Return 0.00%
5-Year Revenue Growth 726.41%
5-Year Earnings Growth -160.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.54 on 05/16/24
Next Earnings Date N/A
Earnings Per Share ttm -1.82
EPS Growth vs. Prev Qtr 18.18%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ZLDPF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -41.49%
Return-on-Assets % -34.80%
Profit Margin % -205.29%
Debt/Equity 0.00
Price/Sales 92.58
Price/Cash Flow N/A
Price/Book 17.36
Book Value/Share 5.15
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar